

Theratechnologies resumes distribution of EGRIFTA® (Tesamorelin for injection) in the United States

September 3, 2014

Montreal, Canada – September 3, 2014 – Theratechnologies Inc. (TSX: TH) is pleased to announce that a first shipment of EGRIFTA® (tesamorelin for injection) was sent to its U.S.- based wholesale distributor in order to replenish the supply chain. As a consequence, EGRIFTA® will once again be available to patients in the United States by mid-September, as planned.

New batches of the 1mg presentation of EGRIFTA® have been manufactured since June. Production of additional batches is already scheduled and will occur over the next weeks and months.